Dr. Dhall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UAMS Medical Center
501 Jack Stephens Drive Jackson T. Stephens Spine and Neuroscience Institute, First Floor
Little Rock, AR 72205Phone+1 501-686-5838Fax+1 501-603-1539
Education & Training
- University of Alabama Medical CenterFellowship, Neuromuscular Medicine (Neurology), 2007 - 2009
- University of Alabama Medical CenterResidency, Neurology, 2004 - 2007
- The University of Texas Health Science CenterMSPH, Epidemiology, 2001 - 2007
- University of Texas Health Science Center at HoustonInternship, Internal Medicine, 2003 - 2004
- All India Institute of Medical SciencesClass of 2000
Certifications & Licensure
- CA State Medical License 2015 - Present
- AR State Medical License 2016 - 2025
- TX State Medical License 2009 - 2025
- FL State Medical License 2015 - 2017
- AZ State Medical License 2009 - 2016
- AL State Medical License 2004 - 2009
- American Board of Psychiatry and Neurology Neurology
- American Association of Physician LeadersCertified Physician Executive
Clinical Trials
- Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders Start of enrollment: 2017 Nov 14
- Open-label Trial in Parkinson's Disease (PD) Start of enrollment: 2021 Feb 24
Roles: Contact
- Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Releas...C Warren Olanow, Robert A Hauser, Daniel J Burdick, Rohit Dhall, Joy Antonelle de Marcaida
Movement Disorders. 2024-02-01 - Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.Alberto J Espay, Robert A Hauser, Rohit Dhall, Sandeep Thakkar, Leslie Cloud
Movement Disorders. 2024-02-01 - 16 citationsSafety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.Andrew McGarry, Shane Rosanbalm, Mika Leinonen, C Warren Olanow, Dennis To
The Lancet. Neurology. 2024-01-01
Press Mentions
- Huntington’s Disease Symposium Details Resources, Seeks Study ParticipantsJanuary 20th, 2023
- After Deep Brain Stimulation Surgery, Arkansas Writer’s Tremors Resume … Until Doctor Activates His ImplantsOctober 11th, 2021
- Utility of Objective Gait Measures in Levodopa‐Unresponsive Freezing in Parkinson'sJanuary 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: